

Management of prostate cancer

Plenary Session 05

Monday, 27 March
07:30 - 10:30

Location: eURO Auditorium (Level 0)

Chairs: A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

Aims and objectives of this session

The aim of this session is to discuss and debate about the role of screening, early detection and optimal treatment of localised prostate cancer. The role of screening based on the most updated results of prospective randomised studies will be debate and different PSA-based approaches will be discussed. In addition, strengths and limits of prostate MRI in improving our ability to detect of clinically significant prostate cancer will be covered. Finally, the optimal management of localised prostate cancer including local treatment and active surveillance will be discussed.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the eURO Auditorium (Level 0). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

07:30 - 08:00

Debate Prostate cancer screening: Time to change recommendations for PSA testing?

07:30 - 07:45

Yes

J. Hugosson, Göteborg (SE)

07:45 - 08:00

No

R.L. Grubb III, St. Louis (US)

08:00 - 08:30

Debate MRI prior to biopsy – Results from the PROMIS trial

08:00 - 08:20

Presenter

H.U. Ahmed, London (GB)

08:20 - 08:30

Discussant

J. Walz, Marseille (FR)

08:30 - 09:00

Debate Should we change our strategy in primary prostate biopsy?

08:30 - 08:45

mpMRI targeted biopsies are sufficient

P.A. Pinto, Bethesda (US)

08:45 - 09:00

Systematic biopsy is essential

G. Ploussard, Toulouse (FR)

09:00 - 09:25

Debate Lessons from the ProtecT trial

09:00 - 09:15

Presenter

F.C. Hamdy, Oxford (GB)

09:15 - 09:25

Discussant: Putting ProtecT into context

N. Mottet, Saint-Étienne (FR)

09:25 - 09:55

Debate Active surveillance for Gleason 3+4 prostate cancer

Moderator:

A. Rannikko, Helsinki (FI)

09:25 - 09:40

Pro (US)

M.R. Cooperberg, San Francisco (US)

09:40 - 09:55

Con (EU)

M. Graefen, Hamburg (DE)

09:55 - 10:15

State-of-the-art lecture Hereditary prostate cancer

P. Walsh, Baltimore (US)

LBN01

The impact of dutasteride/tamsulosin combination therapy on sexual function in sexually active men with benign prostatic hyperplasia

By: [Roehrborn C.G.](#)¹, Manyak M.J.², Palacios Moreno J.M.³, Wilson T.H.⁴, Rosen R.⁵

Institutes:¹UT Southwestern Medical School, Department of Urology, Dallas, United States of America, ²GSK, Washington DC, United States of America, ³GSK, Madrid, Spain, ⁴PAREXEL International, NC, United States of America, ⁵New England Research Institutes, Watertown, MA, United States of America

State-of-the-art lecture

10:25 - 10:30

Discussant:

M. Gacci, Florence (IT)
